Cytek Biosciences Q2 revenue slightly misses estimates

Cytek Biosciences

05/08/2026 22:10

Overview
Cell analysis solutions firm's Q2 revenue rose 6% yr/yr, slightly missing analyst expectations
Company posted a wider Q2 net loss, with adjusted EBITDA turning negative
Cytek raised full-year 2026 revenue outlook midpoint by $1 mln

Outlook
Cytek Biosciences raises 2026 revenue outlook to $207 mln-$212 mln, midpoint up $1 mln

Result Drivers
INSTRUMENT SALES - Strong instrument growth in the U.S. and China drove revenue increase, according to CEO Wenbin Jiang
SERVICE REVENUE - Continued expansion of service business contributed to revenue growth, per CEO Wenbin Jiang
NEW PRODUCT LAUNCHES - Launch of Cytek Borealis and new Aurora Evo configurations supported instrument platform adoption

Company press release: ID:nGNX59jCm7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Miss*
$48.14 mln
$48.61 mln (3 Analysts)
Q2 Net Loss
 
$12.16 mln
 
Q2 Adjusted EBITDA
 
-$1.54 mln
 
Q2 Adjusted Gross Margin
 
59%
 
Q2 Pretax Loss
 
$11.64 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytek Biosciences, Inc. is $5.25, about 22.7% above its August 4 closing price of $4.28

Reuters Recommended Reads
Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand
Aug 4 - Azenta Q3 adjusted EPS beats estimates, revenue rises 12%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)